Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients with Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
- Lihua E. Budde
- , Sarit Assouline
- , Laurie H. Sehn
- , Stephen J. Schuster
- , Sung Soo Yoon
- , Dok Hyun Yoon
- , Matthew J. Matasar
- , Francesc Bosch
- , Won Seog Kim
- , Loretta J. Nastoupil
- , Ian W. Flinn
- , Mazyar Shadman
- , Catherine Diefenbach
- , Carol O'Hear
- , Huang Huang
- , Antonia Kwan
- , Chi Chung Li
- , Emily C. Piccione
- , Michael C. Wei
- , Shen Yin
- City of Hope National Med Center
- McGill University
- University of British Columbia
- University of Pennsylvania
- Seoul National University
- University of Ulsan
- Memorial Sloan-Kettering Cancer Center
- Vall d'Hebron Institute of Oncology
- Sungkyunkwan University
- University of Texas MD Anderson Cancer Center
- Sarah Cannon Research Institute
- Fred Hutchinson Cancer Research Center
- New York University
- Genentech, Inc
- Hoffmann-La Roche Limited
- Washington University St. Louis
Research output: Contribution to journal › Article › peer-review
285
Link opens in a new tab
Scopus
citations